EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome

Darin T Okuda iD, Orhun Kantarci iD, Christine Lebrun-Frénay, Maria Pia Sormani iD, Christina J Azevedo, Francesca Bovis, Le H Hua, Lilyana Amezcua, Ellen M Mowry, Christophe Hotermans, Jason Mendoza iD, John S Walsh und 10 weitere

Annals of Neurology · 2023-03 · 93 (3) · 604-614

DOI: 10.1002/ana.26555 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Neurology, online erschienen am 10.12.2022. Verfasst von Darin T Okuda und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Neuroinnovation Program, Multiple Sclerosis & Neuroimmunology Imaging Program, The University of Texas Southwestern Medical …. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Biogen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The radiologically isolated syndrome (RIS) represents the earliest detectable pre‐clinical phase of multiple sclerosis (MS). This study evaluated the impact of therapeutic intervention in preventing first symptom manifestation at this stage in the disease spectrum.

Methods

We conducted a multi‐center, randomized, double‐blinded, placebo‐controlled study involving people with RIS. Individuals without clinical symptoms typical of MS but with incidental brain MRI anomalies consistent with central nervous system (CNS) demyelination were included. Within 12 MS centers in the United States, participants were randomly assigned 1:1 to oral dimethyl fumarate (DMF) 240 mg twice daily or placebo. The primary endpoint was the time to onset of clinical symptoms attributable to a CNS demyelinating event within a follow‐up period of 96 weeks. An intention‐to‐treat analysis was applied to all participating individuals in the primary and safety investigations. The study is registered at ClinicalTrials.gov , NCT02739542 (ARISE).

Results

Participants from 12 centers were recruited from March 9, 2016, to October 31, 2019, with 44 people randomized to dimethyl fumarate and 43 to placebo. Following DMF treatment, the risk of a first clinical demyelinating event during the 96‐week study period was highly reduced in the unadjusted Cox proportional‐hazards regression model (hazard ratio [HR] = 0.18, 95% confidence interval [CI] = 0.05–0.63, p = 0.007). More moderate adverse reactions were present in the DMF (34 [32%]) than placebo groups (19 [21%]) but severe events were similar (DMF, 3 [5%]; placebo, 4 [9%]).

Interpretation

This is the first randomized clinical trial demonstrating the benefit of a disease‐modifying therapy in preventing a first acute clinical event in people with RIS. ANN NEUROL 2023;93:604–614

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingHumansDimethyl FumarateImmunosuppressive AgentsMagnetic Resonance ImagingDouble-Blind Method

Substanzen

Dimethyl FumarateImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Neurology, Neuroinnovation Program, Multiple Sclerosis & Neuroimmunology Imaging Program, The University of Texas Southwestern Medical Center, Dallas, TX.
  • Department of Neurology, Mayo Clinic, Rochester, MN.
  • Department of Neurology, Universitaire de Nice, Nice, France.
  • Department of Health Sciences, University of Genoa, Genoa, Italy.
  • Department of Health Sciences, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Department of Neurology, University of Southern California, Los Angeles, CA.

ORCID-Profile: Darin T Okuda, Orhun Kantarci, Maria Pia Sormani, Jason Mendoza, Olaf Stüve

Förderung

  • Biogen

Zitieren

APA

Okuda, D. T., Kantarci, O., Lebrun-Frénay, C., Sormani, M. P., Azevedo, C. J., Bovis, F., Hua, L. H., Amezcua, L., Mowry, E. M., Hotermans, C., Mendoza, J., Walsh, J. S., von Hehn, C., Vargas, W. S., Donlon, S., Naismith, R. T., Okai, A., Pardo, G., Repovic, P., …, & Pelletier, D. (2023). Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome. Annals of Neurology, 93(3), 604-614. https://doi.org/10.1002/ana.26555

Vancouver

Okuda DT, Kantarci O, Lebrun-Frénay C, Sormani MP, Azevedo CJ, Bovis F, et al. Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome. Annals of Neurology. 2023;93(3):604-614. doi:10.1002/ana.26555

BibTeX
@article{Okuda2023,
  author = {Okuda, Darin T and Kantarci, Orhun and Lebrun-Frénay, Christine and Sormani, Maria Pia and Azevedo, Christina J and Bovis, Francesca and Hua, Le H and Amezcua, Lilyana and Mowry, Ellen M and Hotermans, Christophe and Mendoza, Jason and Walsh, John S and von Hehn, Christian and Vargas, Wendy S and Donlon, Stacy and Naismith, Robert T and Okai, Annette and Pardo, Gabriel and Repovic, Pavle and Stüve, Olaf and Siva, Aksel and Pelletier, Daniel},
  title = {Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome},
  journal = {Annals of Neurology},
  year = {2023},
  volume = {93},
  number = {3},
  pages = {604--614},
  doi = {10.1002/ana.26555}
}
Kostenlos starten →